HIGHLIGHTS
- who: Zhengyang Yang from the Department of General Surgery, Beijing Friendship Hospital, Capital Medical University and National Clinical Research Center for Digestive Diseases, Beijing, China have published the paper: Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial), in the Journal: (JOURNAL) of 23/05/2021
- what: To explore the curative effect of the treatment strategy, the authors design this single-arm study.
SUMMARY
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.